Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: AGGRENOX

Summary for Tradename: AGGRENOX

Suppliers: see list4
patent expirations by year for

Clinical Trials for: AGGRENOX

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
Status: Completed Condition: Healthy

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Status: Completed Condition: Cerebrovascular Accident

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Status: Completed Condition: Cerebrovascular Accident

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Status: Completed Condition: Stroke

Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Status: Completed Condition: Cerebrovascular Accident

Vascular Access Clinical Trials Data Coordinating Center
Status: Completed Condition: Kidney Failure

Treatment of Supine Hypertension in Autonomic Failure
Status: Recruiting Condition: Hypertension

Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers
Status: Completed Condition: Healthy

Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
Status: Completed Condition: Coronary Arteriosclerosis

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Status: Recruiting Condition: Systemic Lupus Erythematosus

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884Nov 22, 1999RXYes6,015,577<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: AGGRENOX

Drugname Dosage Strength RLD Submissiondate
aspirin and dipyridamoleExtended-release Capsules25 mg and 200 mgAggrenox2/1/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology